IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 6:20 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 6:20 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Accuray's Radixact Now Used by Boise Summit Cancer Center
by Zacks Equity Research
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.
Globus Medical's Robotic Guidance System Gets FDA Approval
by Zacks Equity Research
Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.
Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance
by Zacks Equity Research
The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.
Here's Why Investors Should Buy Edwards Lifesciences Now
by Zacks Equity Research
Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
McKesson Banks on Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson (MCK) entered fiscal 2018 with an assumption of branded inflation in the mid-single digits. Pricing pressure in the independent retail pharmacy channel is a headwind.
BioTelemetry Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
BioTelemetry (BEAT) is putting efforts in product innovation through research and development. The company recently announced the acquisition of LifeWatch AG in a deal valued at about $280 million.
Invacare (IVC) Introduces TDX SP2 Power Wheelchair Globally
by Zacks Equity Research
Invacare Corporation's (IVC) newly launched TDX SP2 Power Wheelchair would greatly help in capturing the highly competitive global wheelchair market.
PRA Health Sciences (PRAH) Prices Secondary Stock Offering
by Zacks Equity Research
PRA Health Sciences' (PRAH) move to procure funds through secondary offering is likely to enhance its bottom line and shareholders' returns.
Varian Medical (VAR) Signs Distribution Deal with Bionix
by Zacks Equity Research
Varian Medical's (VAR) new distribution agreement with Bionix Radiation Therapy would strengthen its radiotherapy business in North America.
Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
by Zacks Equity Research
Solid share price rally following the news suggests that the latest development is likely to buoy Meridian's (VIVO) bottom line and enhance its illumigene platform.
Fresenius Medical Inks $2B Deal to Take Over NxStage Medical
by Zacks Equity Research
Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
IDEXX Laboratories (IDXX) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
IDEXX Laboratories' (IDXX) growth across all its segments in Q2 is encouraging.
Medical Products Earnings Due on Aug 1: IDXX, RMD
by Zacks Equity Research
There are some powerful long-term tailwinds of the medical device industry which have been a major driving force behind the sector's impressive performance over the past few quarters.
Why Earnings Season Could Be Great for IDEXX Laboratories (IDXX)
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
MedTech Stocks to Top Q2 Estimates
by Zacks Equity Research
Most of the MedTech majors are lined up to report their earnings results over the next week.
What's in the Offing for Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.
IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
DENTSPLY SIRONA Renews Canadian Distribution Agreement
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY), a dental solutions company, recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc.
Luminex Gets CE Mark for ARIES Norovirus Assay, Shares Rally
by Zacks Equity Research
Shares of Luminex Corporation (LMNX) gained 1.5% to close at $21.38 after the company announced the receipt of CE-IVD mark for the ARIES Norovirus Assay.
IDEXX Well-Poised on Strong Fundamentals, Global Growth
by Zacks Equity Research
On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
CryoLife Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Leading medical device and tissue processing company, CryoLife, Inc. (CRY) rallied to a new 52-week high of $20.20 on Jun 27, eventually closing a little lower at $19.65.
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company.
Merit Medical Embosphere Gets FDA de novo Classification
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) recently announced the receipt of 513(f)(2) (de novo) classification for Embosphere Microspheres from the FDA to expand its indication in the prostatic artery embolization (PAE) space.